AR088085A1 - Derivados heterociclicos nitrogenados y usos sobre el receptor de histamina - Google Patents

Derivados heterociclicos nitrogenados y usos sobre el receptor de histamina

Info

Publication number
AR088085A1
AR088085A1 ARP120103614A ARP120103614A AR088085A1 AR 088085 A1 AR088085 A1 AR 088085A1 AR P120103614 A ARP120103614 A AR P120103614A AR P120103614 A ARP120103614 A AR P120103614A AR 088085 A1 AR088085 A1 AR 088085A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocyclyl
heteroatoms
carboxyl
amino
Prior art date
Application number
ARP120103614A
Other languages
English (en)
Inventor
Sook Kim Jung
Seong Park Woul
Oh Yoon Dong
Il Lee Won
Jung Kim Hye
Young Han Sun
Su Ho Pil
Oh Ahn Sung
Original Assignee
C & C Res Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C & C Res Lab filed Critical C & C Res Lab
Publication of AR088085A1 publication Critical patent/AR088085A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente se refiere a compuestos heterocíclicos que son de utilidad en la preparación de fármacos para el tratamiento de enfermedades asociadas con diversas funciones del receptor de histamina 4. En especial, los citados fármacos son de utilidad para el tratamiento de enfermedades inflamatorias, alergia, dolor, pólipos nasales, rinitis, sinusitis crónica, congestión nasal, prurito nasal, asma, enfermedad pulmonar obstructiva crónica, artritis reumatoide, dermatitis atópica, psoriasis, eczema, prurito, picazón de la piel, urticaria, urticaria idiopática crónica, escleroderma, conjuntivitis, queratoconjuntivitis, inflamación ocular, sequedad ocular, disfunción cardiaca, arritmia, ateroesclerosis, esclerosis múltiple, enfermedad intestinal inflamatoria (incluso colitis, enfermedad de Crohn, colitis ulcerante), dolor inflamatorio, dolor neuropático, dolor osteoartrítico, enfermedad tiroidea autoinmune, diabetes inmunomediada (también conocida como tipo I), lupus, adherencias posquirúrgicas, trastornos vestibulares y cáncer. Reivindicación 1: Un compuesto heterocíclico de la fórmula (1), o un racemato, un isómero o una sal farmacéuticamente aceptable del mismo, en el cual: cada uno de los siguientes: X¹, X², X³ y X⁴ es, independientemente, C ó N, con la condición de que al menos uno entre X¹, X², X³ y X⁴ sea N, R¹ es un mono- o poli-heterociclilo saturado o insaturado de 3 a 12 miembros, que contiene de 1 a 3 heteroátomos (con preferencia, heteroátomos seleccionados entre N, O y S), donde R¹ está insustituido o sustituido con 1 a 3 sustituyentes seleccionados entre -NR⁶R⁷, -alquil C₁₋₆-NR⁶R⁷ y R⁸; o R¹ se selecciona entre -H, -NR⁶R⁷ y R⁸; R², R³, R⁴ y R⁵ pueden ser iguales o diferentes; y cada uno de ellos se selecciona de un modo independiente entre -H; alquilo C₁₋₆; haloalquilo C₁₋₆; perhaloalquilo C₁₋₆; -amino-alquilo C₁₋₆; cicloalquilo C₃₋₈; -halógeno (-F, -Cl, -Br, -I); -CN; alcoxi C₁₋₆; haloalcoxi C₁₋₆; perhaloalcoxi C₁₋₆; alquenilo-C₂₋₇; alquinilo C₂₋₈; -amino; -amido; alquil C₁₋₆-carboxilo; -carboxilo (-COOH); -acilo C₁₋₆ -OH; -nitro (-NO₂) ; -arilo C₆₋₁₀; -heterociclilo; y -O-alquil C₁₋₆-heterociclilo, donde el heterociclilo es un heterociclilo saturado o insaturado de 3 a 6 miembros, que contiene 1 a 3 heteroátomos (con preferencia, heteroátomos seleccionados entre N, O y S), con la condición de que cuando X¹ sea N, R² no exista; cuando X² sea N, R³ no exista; cuando X³ sea N, R⁴ no exista; y cuando X⁴ sea N, R⁵ no exista; cada uno de los siguientes: Y¹, Y², Y³, Y⁴ e Y⁵ es, independientemente, C o un heteroátomo (con preferencia, un heteroátomo seleccionado independientemente entre N, O y S), con la condición de que al menos uno de los siguientes: Y¹, Y², Y³, Y⁴ e Y⁵ sea un heteroátomo seleccionado independientemente entre N, O y S, cada uno de los siguientes: Y² e Y³ puede sustituirse de un modo independiente con R⁹, Y⁴ puede sustituirse con -H o alquilo C₁₋₆; cada R⁶ y R⁷ se selecciona, independientemente, entre -H; alquilo C₁₋₆ cicloalquilo C₃₋₈; -heterociclilo; -amino-mono- o di-alquilo C₁₋₆; alquil C₁₋₆-amino-mono- o di-alquil C₁₋₆; alquil C₁₋₆-heterociclilo; alquil C₁₋₆-carboxilo; -carboxilo (-COOH); y fenilo, donde el heterociclilo es un heterociclilo saturado o insaturado de 3 a 6 miembros, que contiene 1 a 3 heteroátomos (con preferencia, heteroátomos seleccionados entre N, O y S); R⁸ es alquilo C₁₋₆; alcoxi C₁₋₆; -OH; -amino; -alquil C₁₋₆-amino; cicloalquilo C₃₋₈; -S-alquil C₁₋₆-amino-mono- o di-alquil C₁₋₆; -S-alquil C₁₋₆-heterociclilo; -O-heterociclilo; o -O-alquil C₁₋₆-heterociclilo, donde el heterociclilo es un heterociclilo saturado o insaturado de 3 a 6 miembros, que contiene 1 a 3 heteroátomos (con preferencia, heteroátomos seleccionados entre N, O y S); y R⁹ se selecciona entre-H; -OH; alquilo C₁₋₆ haloalquilo C₁₋₆; perhaloalquilo C₁₋₆; -amino-mono- o di-alquilo C₁₋₆; cicloalquilo C₃₋₇; -heterociclilo; -arilo C₆₋₁₀; heteroarilo de 5 a 12 miembros; alcoxi C₁₋₆; haloalcoxi C₁₋₆; -halógeno (-F, -Cl, -Br, -I); -amino; -amido; -acilo C₁₋₆; -CN; -carboxilo (-COOH); alquil C₁₋₆-carboxilo; y -nitro (-NO₂), con la condición de que cuando Y⁴ sea N e Y¹, Y², Y³ e Y⁵ sea C, Y³ no esté sustituido con un sustituyente que tenga una parte -C(=O)-, donde cada uno de los siguientes grupos: alquilo, cicloalquilo, heterociclilo, alcoxi, alquenilo, alquinilo, acilo y arilo grupos pueden estar independientemente insustituidos o sustituidos con uno o más sustituyentes (por ejemplo, 1 - 3 sustituyentes) seleccionados del grupo que consiste en alquilo C₁₋₄, -halógeno (-F, -Cl, -Br, -I), -CN, alcoxi C₁₋₄, -amino, -amido, -carboxilo (-COOH), -acilo C₁₋₆, -OH, -nitro (-NO₂), heterociclilo y fenilo, donde el heterociclilo es un heterociclilo saturado o insaturado de 3 a 6 miembros, que contiene 1 a 3 heteroátomos (con preferencia, heteroátomos seleccionados entre N, O y S).
ARP120103614A 2011-09-30 2012-09-28 Derivados heterociclicos nitrogenados y usos sobre el receptor de histamina AR088085A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110100369 2011-09-30
KR20120033444 2012-03-30

Publications (1)

Publication Number Publication Date
AR088085A1 true AR088085A1 (es) 2014-05-07

Family

ID=47996667

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103614A AR088085A1 (es) 2011-09-30 2012-09-28 Derivados heterociclicos nitrogenados y usos sobre el receptor de histamina

Country Status (26)

Country Link
US (1) US9586959B2 (es)
EP (2) EP3461825B1 (es)
JP (1) JP6031107B2 (es)
KR (1) KR101800749B1 (es)
CN (1) CN103889986B (es)
AR (1) AR088085A1 (es)
AU (1) AU2012316912B9 (es)
BR (1) BR112014007645A2 (es)
CA (1) CA2848154C (es)
CY (1) CY1121292T1 (es)
DK (2) DK3461825T3 (es)
ES (2) ES2687693T3 (es)
FI (1) FI3461825T3 (es)
HR (2) HRP20230893T1 (es)
HU (2) HUE040374T2 (es)
LT (2) LT2760865T (es)
MX (1) MX355795B (es)
PL (2) PL3461825T3 (es)
PT (2) PT2760865T (es)
RS (2) RS57854B1 (es)
RU (1) RU2628074C2 (es)
SG (1) SG11201400484RA (es)
SI (2) SI2760865T1 (es)
TR (1) TR201814710T4 (es)
TW (1) TWI551600B (es)
WO (1) WO2013048214A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2917262A1 (en) 2013-07-02 2015-01-08 Syngenta Participations Ag Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents
CN103435561B (zh) * 2013-08-19 2016-08-10 上海交通大学 一种新型d-氨基酸氧化酶抑制剂及其制备和应用
CN104016909B (zh) * 2014-04-03 2016-04-20 定陶县友帮化工有限公司 一种2-氨基-3-溴-5-氯吡啶的合成方法
CN104016911A (zh) * 2014-04-03 2014-09-03 定陶县友帮化工有限公司 一种2-氨基-3,5-二溴吡啶的合成方法
CN112010772A (zh) * 2016-01-26 2020-12-01 赵鸣 5-氨基酮戊酸及其衍生物的盐化合物和应用
JP2019520379A (ja) 2016-07-01 2019-07-18 ジー１ セラピューティクス， インコーポレイテッド ピリミジン系の抗増殖剤
US10905675B2 (en) 2016-12-14 2021-02-02 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for prevention, alleviation or treatment of pruritus
WO2018139876A1 (ko) * 2017-01-26 2018-08-02 동화약품주식회사 신규한 [1, 2, 4] 트리아졸로 [4, 3-a]퀴녹살린 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 bet 단백질 관련 질환의 예방 또는 치료용 약학적 조성물
RU2745035C1 (ru) * 2017-02-27 2021-03-18 Бетта Фармасьютикалз Ко., Лтд. Ингибитор fgfr и его применение
TW202021969A (zh) * 2018-05-31 2020-06-16 南韓商Ｃ＆Ｃ新藥研究所 雜環衍生物及其用途
GB2575490A (en) * 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
WO2021236650A1 (en) 2020-05-19 2021-11-25 G1 Therapeutics, Inc. Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
EP4067357A1 (en) * 2021-03-30 2022-10-05 JW Pharmaceutical Corporation Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hydrogen sulfate monohydrate
TW202317568A (zh) * 2021-06-22 2023-05-01 丹麥商理奧藥品公司 1-(8-溴化吡啶并[2,3-e][1,2,4]三唑并[4,3-a]吡嗪-4-基)-n-甲基吖丁啶-3-胺半琥珀酸鹽之新穎結晶形式
WO2024068851A1 (en) * 2022-09-29 2024-04-04 Jw Pharmaceutical Corporation A process for the manufacture of salts and crystalline forms of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine and novel crystalline forms
WO2024069577A1 (en) * 2022-09-29 2024-04-04 Jw Pharmaceutical Corporation Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine
WO2024069576A1 (en) * 2022-09-30 2024-04-04 Jw Pharmaceutical Corporation Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine mono succinate

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831013A (en) * 1986-03-20 1989-05-16 Ciba-Geigy Corporation 2-substituted-e-fused-[1,2,4]triazolo[1,5-c]pyrimidines, pharmaceutical compositions, and uses thereof
US5070086A (en) * 1987-12-23 1991-12-03 Schering Corporation Imidazo- and pyrimido-quinoline, naphthyridine and pyridopyrazine compounds
AU9651198A (en) * 1997-11-11 1999-05-31 Ono Pharmaceutical Co. Ltd. Fused pyrazine compounds
CA2322311C (en) * 1998-03-04 2009-10-13 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
JP2000319277A (ja) * 1999-05-11 2000-11-21 Ono Pharmaceut Co Ltd 縮合ピラジン化合物およびその化合物を有効成分とする薬剤
MXPA05010293A (es) 2003-03-27 2005-11-17 Pfizer Prod Inc 4-amino[1,2,4]triazolo[4,3-a]quinoxalinas sustituidas.
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
WO2009068246A2 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Methods of treating obesity and metabolic disorders
US8466167B2 (en) * 2008-03-03 2013-06-18 Irm Llc Compounds and compositions as TLR activity modulators
AU2009291719A1 (en) 2008-09-10 2010-03-18 Alcon Research, Ltd Heterocyclic inhibitors of histamine receptors for the treatment of disease
CN100580335C (zh) * 2008-09-11 2010-01-13 艾欧史密斯(中国)热水器有限公司 承压式太阳能热水器
US9938268B2 (en) * 2008-12-17 2018-04-10 Merck Patent Gmbh C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
KR101779137B1 (ko) * 2009-01-23 2017-09-18 다케다 야쿠힌 고교 가부시키가이샤 폴리(ａｄｐ-리보스)폴리머라제(ｐａｒｐ) 억제제
US8541417B2 (en) 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2011060207A1 (en) 2009-11-16 2011-05-19 Schering Corporation FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
TW201204727A (en) * 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease

Also Published As

Publication number Publication date
FI3461825T3 (fi) 2023-08-17
CN103889986A (zh) 2014-06-25
ES2954303T3 (es) 2023-11-21
WO2013048214A3 (en) 2013-05-23
SG11201400484RA (en) 2014-10-30
PL2760865T3 (pl) 2018-12-31
RU2014115478A (ru) 2015-11-10
DK2760865T3 (en) 2018-10-08
EP3461825A1 (en) 2019-04-03
SI2760865T1 (sl) 2018-10-30
HUE040374T2 (hu) 2019-03-28
PL3461825T3 (pl) 2023-10-30
EP2760865A4 (en) 2015-03-18
HRP20181310T1 (hr) 2018-10-19
AU2012316912A1 (en) 2014-03-20
WO2013048214A2 (en) 2013-04-04
AU2012316912B9 (en) 2017-04-27
EP2760865B1 (en) 2018-07-11
KR101800749B1 (ko) 2017-11-24
BR112014007645A2 (pt) 2017-04-18
US9586959B2 (en) 2017-03-07
JP6031107B2 (ja) 2016-11-24
EP3461825B1 (en) 2023-06-07
HRP20230893T1 (hr) 2023-11-24
MX2014003042A (es) 2014-05-28
RS57854B1 (sr) 2018-12-31
CA2848154C (en) 2020-04-28
PT2760865T (pt) 2018-11-05
LT2760865T (lt) 2018-09-25
TWI551600B (zh) 2016-10-01
SI3461825T1 (sl) 2023-11-30
MX355795B (es) 2018-04-30
KR20140090984A (ko) 2014-07-18
LT3461825T (lt) 2023-08-25
AU2012316912B2 (en) 2017-04-20
TR201814710T4 (tr) 2019-01-21
TW201321381A (zh) 2013-06-01
CN103889986B (zh) 2017-07-21
DK3461825T3 (da) 2023-08-14
US20140315888A1 (en) 2014-10-23
RU2628074C2 (ru) 2017-08-14
JP2014531458A (ja) 2014-11-27
AU2012316912A8 (en) 2014-04-10
ES2687693T3 (es) 2018-10-26
HUE062842T2 (hu) 2023-12-28
CA2848154A1 (en) 2013-04-04
PT3461825T (pt) 2023-09-11
EP2760865A2 (en) 2014-08-06
RS64575B1 (sr) 2023-10-31
CY1121292T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
AR088085A1 (es) Derivados heterociclicos nitrogenados y usos sobre el receptor de histamina
AR089285A1 (es) Derivados de betulina
CL2017002609A1 (es) Compuestos derivados de pirazolopiridina hidrogenadas, inhibidores p2x7, composición farmacéutica que los comprende; proceso de preparación de estos; y su uso en el tratamiento de enfermedades oseas, sns, cardiovasculares, entre otras (divisional de cl 2655-2015)
AR087052A1 (es) Derivados de amina ciclica como antagonistas del receptor ep4
CU20160097A7 (es) Compuestos de imidazopirazina como inhibidores de syk
AR107032A1 (es) Inhibidores bicíclicos de pad4
AR109295A1 (es) Compuestos tricíclicos que contienen nitrógeno y usos de los mismos en medicina
AR104307A1 (es) Tetralinas de ácido 3-espirocíclico-6-hidroxámico como inhibidores de hdac
AR110674A1 (es) Nucleósidos, nucleótidos sustituidos y análogos de los mismos
AR096788A1 (es) Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
JP2016518448A5 (es)
AR089527A1 (es) Inhibidores de bromodominios
AR090191A1 (es) Derivados del acido fenil alcanoico como agonistas gpr
AR094300A1 (es) Derivados de quinolonas
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR095310A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AR110038A1 (es) Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos
AR092319A1 (es) Carbazoles que contienen sulfonamidas como moduladores de criptocromo
AR099640A1 (es) Derivados de pirrolopiridina o pirazolopiridina
AR083543A1 (es) Diamidas de amino-pirrolidin-azetidinas, composiciones farmaceuticas que las contienen y uso de las mismas para tratar dolores inflamatorios
AR085750A1 (es) Derivados de pirazolo-pirimidina
AR103598A1 (es) Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac
AR110241A1 (es) Ácidos indanilaminopiridil-ciclopropano-carboxílicos, composiciones farmacéuticas y usos de los mismos
PE20191490A1 (es) DERIVADOS DE LA PIRIMIDIN ENONA TRICICLICA PARA LA INHIBICION DE RORy Y OTROS USOS

Legal Events

Date Code Title Description
FG Grant, registration